Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer

Radiology

Volumn 252, Issue 3, 2009, Pages 729-736

  Hövels, Anke M ^a   Heesakkers, Roel A M ^a   Adang, Eddy M M ^a   Barentsz, Jelle O ^a   Jager, Gerrit J ^b   Severens, Johan L ^c,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; HEALTH CARE COST; HUMAN; IMAGING SYSTEM; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOGRAPHY; MAGNETIC RESONANCE LYMPHOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR;

AGED; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; LIFE EXPECTANCY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MARKOV CHAINS; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY;

EID: 70349266132     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2531071360     Document Type: Article

References (19)

1. Narayan P, Fournier G, Gajendran V, et al. Utility of preoperative serum prostate specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 1994;44:519-524.
2. Harisinghani MG, Barentsz JO, Hahn PF, et al. Noninvasive detection in clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-2499. (Pubitemid 36706536)
3. Heesakkers RA, Hövels AM, Jager GJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008;9:850-856.
4. Hunink MG, Krestin GP. Study design for concurrent development, assessment, and implementation of new diagnostic imaging technology. Radiology 2002;222:604-614.
5. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-551.
6. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994;151:1315-1320.
7. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Dutch manual for costing research, methods, and guideline prices. Amstelveen, the Netherlands: Health Insurance Board, 2000.
8. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programs. 3rd ed. Oxford, England: Oxford Medical Publications, 2005.
9. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003;41:153-164.
10. CBS Statline Mortality 2000-2004. http://statline.cbs.nl. Accessed September 18, 2006.
11. Hunink MG, Bult JR, de Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998;18:337-346.
12. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004;13:405-415. (Pubitemid 38660390)
13. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: a introduction to statistical issues and methods. Stat Methods Med Res 2002;11:455-468.
14. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994;3:309-319.
15. Severens JL, Brunenberg DE, Fenwick EA, O'Brien B, Joore MA. Cost-effectiveness acceptability curves and a reluctance to lose. Pharmacoeconomics 2005;23:1207-1214. (Pubitemid 41803317)
16. Willan AR, O'Brien BJ, Levya RA. Cost-effectiveness analysis when the WTA is greater than the WTP. Stat Med 2001;20:3251-3259.
17. O'Brien BJ, Gertsen K, Willan AR, Faulkner LA. Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Econ 2002;11:175-180.
18. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
19. Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localized prostate cancer: a systematic review. Health Technol Assess 2003;7:iii, ix-x, 1-157. (Pubitemid 37492815)